Filed: 2026-04-14 AccNo: 0001437749-26-012238 Size: 5 KB
NS
Article DetailSEC EDGAR Filings
SEC EDGAR Filings
4 - Wainman Paul R
Filed:
2026-04-16
AccNo:
0001437749-26-012551
Size:
5 KB
发布时间04/16 19:57 UTC
首次发现04/16 20:01 UTC
热度106.3
重要度74
情绪0.00
站内整理正文
优先显示结构化正文；如果正文还未抽出，则回退到摘要。
sec_edgar_index_v1 · 532 字符
Form 4 - Statement of changes in beneficial ownership of securities: SEC Accession No. 0001437749-26-012551
Filing Date: 2026-04-16
Accepted: 2026-04-16 15:57:41
Documents: 1
Period of Report: 2026-04-15
IMMUCELL CORP /DE/ ( Issuer ) CIK : 0000811641 (see all company filings) EIN. : 010382980 | State of Incorp.: DE | Fiscal Year End: 1231 SIC : 2835 In Vitro & In Vivo Diagnostic Substances (CF Office: 03 Life Sciences)
1 | FORM 4 WAINMAN, PAUL 04/15/26 | rdgdoc.html | 4
1 | FORM 4 WAINMAN, PAUL 04/15/26 | rdgdoc.xml | 4
同簇相关文章
从当前文章回到同一事件簇里的其他来源或补充材料。
1 篇